tbuckley/cabot-search huggingface dataset:
Abstract P242: US Secular Trends in Coronary Heart Disease, Heart Attack/Myocardial Infarction, and Stroke Prevalence, by Race/Ethnicity, 2005-2010
Authors: Bertha Hidalgo
Journal: Circulation (2013)

Background: Cardiovascular disease (CVD) trends are important for the evaluation of disease burden in the context of health disparities. The US has become increasingly diverse in the last few decades, calling for a greater understanding of secular trends in coronary heart disease (CHD), heart attack (HA)/myocardial infarction (MI), and stroke, particularly among Hispanics. For this study, the main objective is to identify secular trends in CVD between 2005-2010 by race/ethnicity, with focus on Hispanic men and women, to shed light on the epidemiological phenomenon known as the Hispanic Paradox. Methods: Data from the Behavioral Risk Factor Surveillance Survey was used to assess secular trends between 2005 and 2010. Respondents of the survey were 18 years of age or older and all data was self-report. The telephone survey was conducted cross-sectionally each year. Questions included, “Ever diagnosed with angina or coronary heart disease?” “Ever diagnosed with stroke?” and “Ever diagnosed with a heart attack?”. Means, frequencies, chi-square tests, and Cochran-Armitage trend tests were performed to assess comparisons across groups and to determine statistical significance for trends. Results: Data in this study were weighted to account for over- and under-representation of ages, race, and income. There were statistically significant differences in prevalence between race/ethnicities for all years, with Hispanics having the lowest prevalence of all three conditions compared to the other races. Among Hispanics, there were statistically significant differences between genders, with men having higher prevalence of CHD/Angina, HA/MI, and stroke than women. No significant trends were found, other than between 2008 and 2010 in all races for CHD/Angina. Conclusions: Overall, there were no significant secular trends for CHD/Angina, HA/MI, or stroke among Hispanics in this study. However, the consistently low prevalence over time of CVD among Hispanics, as compared to other African Americans and Caucasians in this sample, may indicate that more attention is needed for relevant social determinants of health in this population. Furthermore, this data may help to further strengthen support for the Hispanic Paradox, though these results should be interpreted within the limitations inherent to the dataset.
Abstract 14770: Secreted Frizzled Related Protein 2 Reduces Resident Cardiac Progenitor Cell Proliferation and Induces Cardiac Marker Expression
Authors: Jeffrey Schmeckpeper, Farideh Beigi, Zhiping J Zhang, Maria Mirotsou, Richard E Pratt, Victor J Dzau
Journal: Circulation (2010)

Introduction:  Endogenous repair via activation of resident cardiac progenitor cells represents an attractive therapeutic approach for limiting cardiac remodeling and enhancing cardiac regeneration post infarction. Secreted Frizzled Related Protein 2 (Sfrp2) has been shown to reduce myocyte apoptosis and to affect infarct size  in vivo , but its effect on resident cardiac progenitor cells has yet to be investigated. In this study, we examined the effects of Sfrp2 in the proliferation and differentiation of mouse resident cardiac progenitor cells (mCPCs).   Methods:  cKit+/Sca1+ mCPCs were isolated by magnetic beads and single cell clones were derived after plating cells by limiting dilutions. Expression of stem cell and mesenchymal markers was evaluated by FACS analysis and  Sfrp s by qRT-PCR. To examine the effects of Sfrp2 on mCPC proliferation, cell cycle was assessed by BrdU incorporation and DNA content staining using FACS analysis and confirmed by BrdU ELISA. The effect of Sfrp2 on mCPC differentiation was evaluated by both qRT-PCR and immunofluorescent staining for cardiac markers Nkx2.5, Actinin, and α-MHC.   Results:  Isolated mCPC clones maintained expression of Sca1, CD44, CD105, CD29 and CD106 throughout the study. These cells expressed high levels of  Sfrp1  and  3 .  Sfrp2  was detectable but at significantly lower levels. Treatment of mCPCs with 1–100 nM recombinant Sfrp2 protein showed a dose dependent reduction in the percent of cells in S-phase (maximum reduction at 10 nM of 35–40%, P   Conclusions:  Our data suggests that Sfrp2 induces cell cycle arrest of mCPCs by specifically blocking progression of cells from the G0/G1 to S-phase without effecting cell division. This inhibition in proliferation is accompanied by induction of mCPC differentiation as evident by increased expression cardiac specific markers, such as Nkx2.5, but Sfrp2 failed to drive these cells to fully differentiate to mature cardiomyocytes.
Controlled investigation of the amobarbital interview for catatonic mutism [published erratum appears in Am J Psychiatry 1992 May;149(5):720]
Authors: W V McCall, F E Shelp, W M McDonald
Journal: American Journal of Psychiatry (1992)

Clinical reports over the last 60 years suggest that the amobarbital interview is effective in relieving catatonic symptoms. This has never been substantiated with methodologically sound trials. The authors postulated that a randomized blind comparison of intravenous amobarbital and saline would demonstrate the superiority of amobarbital in relieving catatonic mutism.The subjects were 20 inpatients with catatonic mutism. They were randomly assigned to either saline (N = 10) or a 5% amobarbital solution (N = 10), and the infusions were administered intravenously at a rate of 1 cc/min or less over 10 minutes by a blinded physician. A second blinded physician administered a semistructured interview during the infusion to control for the effect of suggestion. A third blinded physician rated patient responsiveness, reactivity, and arousal. Any patient who was unresponsive to the initial infusion was crossed over to the other infusion. Interviews were videotaped for determination of interrater reliability.In the initial infusions, six of 10 patients responded to amobarbital and zero of 10 responded to saline. Four of the saline nonresponders responded when given amobarbital. Response was evident by the 4th minute of the amobarbital infusion. Interrater reliability was high. The responders and nonresponders differed significantly in the variance of the weight-adjusted amobarbital dose, and the responders tended to be older and female.Intravenous amobarbital is superior to saline in relieving catatonic mutism, although only 50% of these patients responded. The nonresponders were distinguished from the responders by a greater variance in the weight-adjusted dose of amobarbital.
Abstract 2714: Heart Failure Device Therapy: Effect of Age and Gender on Patient Survival
Authors: Kismet D Rasmusson, Abdallah G Kfoury, Thomas K French, Jennifer J Connolly, Douglas M Hanson, Colleen A Roberts, Richard Ensign, Brian G Crandall, R. S Evans, Benjamin D Horne, Dale G Renlund
Journal: Circulation (2007)

Background : Indications for heart failure (HF) device therapy are well-established. Cardiac resynchronization therapy (CRT) and internal cardiovertor defibrillator (ICD) use, alone or in combination, reduce morbidity and mortality. However, the frequency of device implantation in situations with limited survival is unknown. This study assessed, in an unselected population, what proportion of patients had a &lt; 1 year survival and whether such survival was affected by age or gender after HF device therapy. Methods : All patients admitted from 2000 –2006 to a referral center for de novo HF device therapy were identified using ICD-9 codes: 0050 (CRT), 0051 (CRT &amp; ICD), and 3794 (ICD). Mortality rates were estimated using Kaplan Meier product limit estimation and between group comparisons for gender and age were made using logistic regression. Results : From 2000 to 2006, 1,735 patients received CRT, ICD, or CRT &amp; ICD. Of these, 1,331 (77%) were men and averaged 66.7 years of age while the women averaged 64.7 years (p = 0.347). One-year survival for all patients was 91%. One-year mortality by age and gender (see Table ), demonstrates that the proportion deriving a less than one year survival benefit after device implantation increases with age, but is not affected by gender. Conclusions : One-year survival after HF device implantation is high, suggestive of appropriate patient selection. However, advanced age increases the likelihood of deriving a shorter term benefit of device therapy, suggesting that careful patient selection is particularly important in older adults to avoid the futile use of expensive technologies. While no apparent gender differences were found related to survival, the overwhelming majority of devices were implanted in men, suggesting gender bias, gender-based co-morbidities affecting care, or gender-based differences in care preferences. Table
Abstract 4841: Natural History of Isolated Noncompaction of the Ventricular Myocardium in Adults. Data from the Societa Italiana di Ecografia Cardiovascolare (SIEC) Registry
Authors: Giovanni Corrado, Giovanni Fazio, Elisabetta Zachara, Claudio Rapezzi, Luca Sormani, Scipione Carerj, Sandro Beretta
Journal: Circulation (2008)

Isolated ventricular noncompaction (IVNC) is a rare cardiomyopathy commonly believed due to intrauterine arrest of compaction of the loosely interwoven meshwork of myocardial fibers. Most studies s...
GCP-2–induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR+-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling
Authors: Rotem Feniger-Barish, Dan Belkin, Alon Zaslaver, Shira Gal, Mally Dori, Maya Ran, Adit Ben-Baruch
Journal: Blood (2000)
Abstract 8661: Dietary Omega-3 Fatty Acids Prevent the Association Between Impaired Fetal Growth and Arterial Wall Thickening in Children: A Randomized Controlled Trial
Authors: Michael Skilton, Julian G Ayer, Jason A Harmer, Karen Webb, Stephen R Leeder, Guy B Marks, David S Celermajer
Journal: Circulation (2011)

Introduction: Impaired fetal growth is an independent cardiovascular risk factor, and is associated with early arterial wall thickening in young children. No preventive strategy has been identified. Hypothesis: That dietary omega-3 fatty acid supplementation during early childhood will prevent the association between impaired fetal growth and carotid arterial wall thickening in childhood. Methods: The CAPS study was a trial in 616 newborns randomized to one of two daily 500mg oil supplements, from the start of bottle feeding or 6-months of age until 5-years of age. The omega-3 group received a fish oil supplement and canola-based margarines / cooking oils; the control group received sunflower oil supplement and omega-6 fatty acid rich margarines / cooking oils. Children born at term were recruited antenatally from hospitals in Sydney, Australia, between September 1997 and December 1999. 363 non-diabetic children with birth weight &lt;90th centile participated in the CardioCAPS substudy at age 8 years (control group: n=176; omega-3 group: n=187). Primary comparison was an analysis of heterogeneity between groups for the association of fetal growth (birth weight adjusted for gender and gestational age) with ultrasound measured carotid artery intima-media thickness (IMT), at age 8 years. Results: In the control group, fetal growth was inversely associated with carotid IMT (β-coefficient = -0.027 mm [SE 0.013] per kg birth weight, P=0.04), but this association was prevented in the omega-3 group (β-coefficient = 0.014 mm [SE 0.012] per kg birth weight, P=0.24). This association differed significantly between the two groups (figure). Conclusion: The inverse association of fetal growth with early arterial wall thickness may be prevented by dietary omega-3 fatty acid supplementation over the first 5 years of life. Figure. Dietary omega-3 fatty acids mitigate the inverse association of fetal growth with carotid IMT in childhood.
Outlines of Pathology in Its Historical, Philosophical and Scientific Foundations. A Guide for Students and Practitioners of Medicine.
Authors: Horst Oertel
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study
Authors: O. Fitoussi, F. Guichard, S. Hirt, N. Dohollou, C. Bureau, F. Auduhy, P. Guichard
Journal: Journal of Clinical Oncology (2008)

16027 Background: Standard docetaxel-based treatment for mHRPC is not without toxicity, especially in older, poor health status patients. We evaluated the efficacy and safety of combined estramustine, paclitaxel, and tegafur-uracil (ETU) in this population. Methods: This Gehan 2-stage study aimed to recruit 60 chemonaive patients with progressive disease after hormone therapy (new metastatic lesions or PSA progression). Patients received iv paclitaxel 80mg/m2 (days 1, 8, 15), oral tegafur-uracil (UFT) 300 mg/m2/d (250 mg/m2/d cycle 1) plus leucovorin 75 mg/d (in 3 divided doses on days 1–21), and estramustine 280 mg/d (days -1, 0, 1) every 28 days. The primary endpoint was PSA response (PSA reduction of >50%). Results: 58 patients (median age 71 years [range 43–84], 67% with ≥2 lines of hormone therapy, 71% with PS >1) were evaluable for safety. Median Gleason score was 8, median PSA was 221ng/mL and 96% of patients had bone metastases. Patients received a mean of 7 cycles (range 1–22). Response to treatment is shown in the table; 51% and 27% of patients were alive at 12 and 18 months, respectively. ETU was well tolerated, with grade 3/4 anemia, neutropenia, and thrombocytopenia in 9%, 2%, and 2% of patients, respectively. Main non-hematologic side effects (all grades) were alopecia (36%), diarrhea (32%), nausea/vomiting (17%), neuropathy (12%), and skin toxicity (12%). There was no hand-foot syndrome. The addition of tegafur-uracil did not add to the toxicity of paclitaxel-estramustine. Conclusions: The combination of estramustine, paclitaxel, and tegafur-uracil (ETU) is a very promising treatment, with durable responses in patients with mHRPC. ETU is well tolerated, with no life-threatening adverse events or hand-foot syndrome. This combination is an attractive treatment option for patients with mHRPC. Outcome Assessment 3 months 6 months 12 months No. of evaluable patients 41 29 12 Reduction in PSA level, n (%) ≥50% 19 (46) 14 (48) 6 (50) ≥75% 11 (27) 9 (31) 4 (33) Normalization 0 6 (21) 3 (25) Response in non-bony disease, n (%) * Evaluable patients – 20 – Complete response – 3 (15) – Partial response – 9 (45) – Minor response – 2 (10) – Stable disease – 3 (15) – Progressive disease – 2 (10) – * Response in non-bony disease assessed at 6 months only Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Merck Lipha Sant[00e9]
Abstract 14863: Poor Neighborhood Economic Conditions and Perceived Neighborhood Safety are Associated with Cardiometabolic Risk Factors and Insulin Resistance among African Americans in the Jackson Heart Study
Authors: Cheryl R Clark, Mark J Ommerborn, DeMarc A Hickson, Mario Sims, Kya N Grooms, Herman A Taylor, Michelle A Albert
Journal: Circulation (2012)

Introduction: Cardiometabolic risk factors (CMRs) are prevalent among African Americans (blacks) in the southeastern United States (US) and may contribute to their relatively higher rates of heart ...
Abstract 3974: Rapid and Direct Effect of Pioglitazone on Endothelial Function in Patients with Metabolic Syndrome
Authors: Hirotaka Nagashima, Yasuhiro Ishii, Hideki Ueno, Chikaya Omichi, Akiko Ishige, Ayako Yamada, Yoshiko Kakizawa, Takeshi Tanaka, Katsuo Kanmatsuse, Masahiro Endo
Journal: Circulation (2006)
Abstract 19049: Net Clinical Benefit of Vorapaxar in NSTE ACS: Role of Ischemic and Bleeding Risk Stratification
Authors: Pierluigi Tricoci, Zhen Huang, Frans Van de Werf, Harvey White, David Moliterno, Basil Lewis, Claes Held, Christoph Bode, Hisao Ogawa, Yuliya Lokhnygina, Philip Aylward, Lars Wallentin, Robert Harrington, Kenneth Mahaffey, Paul Armstrong
Journal: Circulation (2012)

Background: In 12,944 NSTE ACS pts included in the TRACER trial, platelet protease-activated-receptor 1 (PAR-1) antagonist vorapaxar, on top of standard of care with high thienopyridine use, was associated with an 11% reduction in CV death, MI, or stroke and an increased risk of bleeding. The trial was broadly inclusive and did not exclude pts based on bleeding risk. We evaluated the net clinical benefit of vorapaxar in the randomized population and according to patients’ predicted risks of ischemic events and major bleeding. Methods: Using multivariable models developed in the TRACER placebo group to predict 1-yr major bleeding (GUSTO severe or TIMI major bleeding) and recurrent ischemic events (composite of CV death, MI, stroke), patients were stratified into 2 bleeding risk categories (predicted rate &gt;5% vs ≤5%) and 2 ischemic risk categories (predicted rate &gt;13% vs ≤13%). Net clinical outcome was measured as the difference in treatment effects on the composite ischemic endpoint vs bleeding outcome. Results: Overall at 1-yr, vorapaxar resulted in a 1.30% absolute reduction in CV death, MI, and stroke and a 0.94% absolute increase in GUSTO severe bleeding (net benefit +0.34%). In pts with an increased risk of bleeding, vorapaxar had negative net clinical benefit (Figure). Among pts with high risk of ischemic events but low risk of bleeding (26% of the population), vorapaxar produced a favorable 2.8% absolute net benefit. Conclusion: Vorapaxar was associated with an improved net benefit in a selected but large group of NSTE ACS patients with high risk of recurrent ischemic events and low risk of bleeding, identified through the application of multivariable risk stratification strategies. Appropriate selection of patients in NSTE ACS, with the risk of bleeding balanced against that of recurrent ischemic events, appears to be a determinant of improved outcome with vorapaxar added to standard of care and high use of dual antiplatelet therapy.
Abstract 15387: Bone Marrow-Derived Kruppel-Like Factor 10 (KLF10) Controls Re-Endothelialization in Response to Arterial Injury
Authors: Akm K Wara, André Manica, Julio F Marchini, Xinghui Sun, Basak Icli, Yevgenia Tesmenitsky, Kevin Croce, Mark W Feinberg
Journal: Circulation (2011)

Background: Emerging evidence demonstrates that endothelial progenitor cells (EPCs) may originate from the bone marrow and are capable of being recruited to sites of vascular injury and contribute ...
Abstract 8166: Elevated N-Terminal Pro-Brain Natriuretic Peptide Increases the Risk of Recurrent Thromboembolic Events After Acute Pulmonary Embolism
Authors: Yong Wang, Zhinghong Liu
Journal: Circulation (2011)

Introduction: N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is a predictor of short-term clinical adverse outcome in patients with acute pulmonary embolism (APE), but its long-term prognostic value remains largely undefined. Hypothesis: We assessed the hypothesis that elevated plasma NTproBNP level is associated with recurrent venous thromboembolism (VTE). Methods: On admission, NTproBNP levels were measured in 224 consecutive patients with the first episode of acute pulmonary embolism occurring from January 2005 through October 2010. Patients were categorized to two groups by NTproBNP reference range and followed up at 3, 6, and 12 months and yearly thereafter. The primary end point was symptomatic, recurrent fatal or nonfatal VTE. Results: NTproBNP was elevated in 158 (71%) patients and not elevated in 66 (29%) patients. After a mean follow-up period of 31.0±19.4 months, patients with elevated NTproBNP showed an increased risk of recurrent VTE (20 patients, 12.7%) compared with those not elevated (only 1 patient, 1.5%) ( P =0.009). 6 of 7 deaths related to pulmonary embolism occurred in patients with NTproBNP elevated, compared with patients with NTproBNP normal (1 of 7 deaths, P=0.64). At multivariate analysis stratified by oral anticoagulant treatment duration, elevated NTproBNP was an independent predictor of recurrent VTE (hazard ratio; 10.50; P =0.02). Conclusions: Elevated NTproBNP is associated with the increased risk of VTE recurrence in acute pulmonary embolism patients.
Lesson of the Week: Cardiac arrest due to severe hyperkalaemia in patient taking nabumetone and low salt diet
Authors: B. Pal, A. Hutchinson, A. Bhattacharya, A. Ralston
Journal: BMJ (1995)

We describe the case of a woman with underlying renal insufficiency who developed hyperkalaemia while taking a non-steroidal anti-inflammatory drug and, probably more importantly, a low salt preparation that was also high in potassium. Case reportThis 70 year old woman had suffered from seropositive, erosive rheumatoid arthritis for about 17 years, mainly managed with non-steroidal anti- inflammatory drugs and simple analgesics.She developed hypertension about three years before presentation but had not been taking any regular antihypertensive treatment.Six years previously she had been investigated for haematuria but no lesions were found in the urinary tract.Recently she had been reassessed after a flare-up of her arthritis, and her naproxen was changed to nabumetone 500 mg twice daily.She had been taking it for one month when she was admitted for further assessment of her rheumatoid disease.Mild renal insufficiency was found, with a serum creatinine concentration of 148 pLmol/l and a potassium concentration of 5-7 mmol/l.Dipstick urine This is the second in a short series introducing medical practitioners to the Internet
Abstract 539: Multiple Small Calcifications on Non-contrast CT in Asymptomatic Patients Who Subsequently Experience Adverse Cardiovascular Events
Authors: Damini Dey, Victor Y Cheng, Jamal Rana, Piotr J Slomka, Heidi G Gransar, David Choi, Ryo Nakazato, Nathan D Wong, Leslee J Shaw, Alan Rozanski, Daniel S Berman
Journal: Circulation (2009)
597. Co-Transfection of Human Hepatocyte Growth Factor and Prostacyclin Synthase Gene Enhanced Therapeutic Angiogenesis in Rat and Rabbit Ischemia Model
Authors: Hiromi Koike, Naruya Tomita, Sota Iguchi, Yasufumi Kaneda, Toshio Ogihara, Ryuichi Morishita
Journal: Molecular Therapy (2003)